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Mood and anxiety disorders are the most frequent psychiatric
comorbidities in patients with epilepsy (PWE), with lifetime prevalence
rates ranging between 30% and 35% [1]. Accordingly, we would expect
that antidepressant drugs would be frequently prescribed for these
patients, particularly since most of these drugs can yield a therapeutic
effect in depressive and anxiety disorders. Yet, such is not the case,
and one of the reasons stems from a long-standing misconception
held by clinicians that antidepressant drugs cause seizures. This false
belief constitutes one of the obstacles in the pharmacologic treatment
of mood and anxiety disorders in PWE. Furthermore, data from sev-
eral animal models of epilepsy have suggested that drugs of the sero-
tonin reuptake inhibitor (SSRI) and tricyclic antidepressant (TCA)
families may yield an antiepileptic effect [2,3]. The ﬁrst part of this
review summarizes the data on the impact of antidepressant drugs
on seizures in experimental studies and in patients with and without
epilepsy. In the second part, we highlight special considerations that
need to be taken into account when antidepressants are used in
PWE.
2. Do antidepressant drugs really have proconvulsant properties?
The “proconvulsant effect” of antidepressant drugs is oneof themost
misunderstood facts in the practice of medicine, which unfortunately
has had dire consequences as it has precluded many physicians from
prescribing these psychotropic drugs to PWE. The fact is that, with theunder the CC BY-NCexception of four drugs (see below), the reported seizures associated
with antidepressants have occurred when taken at very high doses
(e.g., in the setting of overdoses) [4,5]. For example, one study revealed
that theminimumcitalopramdose associatedwith seizureswas 400mg
[6]. In fact, this observation has been supported experimentally in a
study of pilocarpine-induced seizures in rats in which hippocampal
perfusion of serotonin (5-HT), up to extracellular concentrations
above 900% of baseline, worsened seizures. On the other hand, at con-
centrations ranging from 80% to 350% of baseline levels, 5HT protected
these rats from seizures [7].
The inclusion of seizures as an iatrogenic effect of antidepressants
(including SSRIs and SNRIs) in the Physician Desk Reference has
perpetuated the concern of prescribing these drugs to PWE since this
document does not clarify the conditions under which seizures tend
to occur. Furthermore, seizures in patients with a primary mood and
anxiety disorder may have resulted from an unidentiﬁed medical and/
or neurologic condition and yes, from the underlying psychiatric
disorder. Indeed, in the last two decades, several population-based
studies have suggested that mood and anxiety disorders may be a risk
factor for the development of epilepsy [8–11]. Interestingly enough,
these data support an observation made by Hippocrates twenty-six
centuries ago when he wrote “melancholics ordinarily become epileptics
and epileptics melancholics:what determines the preference is the direction
the malady takes; if it bears upon the body, epilepsy, if upon the intelligence,
melancholy” [12]. In other words, these studies suggest the existence of a
bidirectional relation between epilepsy and psychiatric disorders
whereby not only are PWE at greater risk of developing these psychiatric
disorders, but patients with primary mood and anxiety disorders have a
two- to seven-fold higher risk of developing epilepsy. This phenomenon-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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occurrence of a seizure in a depressed or anxious patient who is being
treatedwith an antidepressant drugmay be the expression of the natural
course of these psychiatric disorders and not of an iatrogenic effect of the
psychotropic drug.
The proconvulsant effect of antidepressant drugs was clariﬁed in a
pivotal study by Alper et al., who reviewed data from the Food and
Drug Administration Phases II and III clinical regulatory trials of several
TCAs, SSRIs, the serotonin–norepinephrine reuptake inhibitor (SNRI)
venlafaxine, the α2 antagonist mirtazapine, and the norepinephrine–
dopamine reuptake inhibitor bupropion in patients with primary
depression [14]. These investigators compared the incidence of epileptic
seizures between patients randomized to the antidepressant drug and
to a placebo, and they found a signiﬁcantly lower seizure incidence
among patients assigned to antidepressants (standardized incidence
ratio = 0.48, 95% CI, .36–.61). While the seizure incidence was greater
in patients randomized to the drug and the placebo than the published
incidence of unprovoked seizures in the general population, the seizure
incidence was 19-fold higher among patients randomized to the place-
bo. These data support the increased risk of depressed patients for
the development of unprovoked seizures and epilepsy alluded to
above and suggest a protective effect of SSRIs and SNRIs. The two anti-
depressant drugs associated with a higher incidence of seizures than
the placebo included clomipramine and bupropion. Separate reports
had made a similar observation with respect to bupropion (0.5%–4.8%
in a dose-dependent manner) and clomipramine (1%–12.2% in a dose-
dependent manner) and had identiﬁed amoxapine and maprotiline
(incidence: 15.6% in a dose-dependent manner) as two other antide-
pressant drugs associated with an increased risk of seizures [3]. In
summary, with the exception of these four drugs, antidepressant
drugs are safe for PWE when used at therapeutic doses.
3. Do antidepressant drugs have antiepileptic properties?
Antidepressant drugs, in particular SSRIs and SNRIs, have become
theﬁrst line of treatment of depression and anxiety disorders in patients
with andwithout epilepsy [15]. Furthermore, antiepileptic properties of
SSRIs have been suggested in several experimental studies, which are
brieﬂy reviewed below.
The primary pharmacodynamic aim of SSRIs and SNRIs is to increase
the synaptic concentration of monoamines, in particular 5HT and
norepinephrine (NE). Thus, to demonstrate potential antiepileptic prop-
erties, it would be necessary to demonstrate the following: (i) a patho-
genic role of serotonergic and/or noradrenergic mechanisms in seizure
activity, (ii) a role of monoamines in the antiepileptic effects of antiep-
ileptic drugs (AEDs), and (iii) an antiepileptic effect of SSRIs and SNRIs
in several animal models of epilepsy and in double-blind randomized
placebo-controlled trials of these drugs in PWE. Of these three condi-
tions, nodata are yet available on controlled trials of these drugs in PWE.
3.1. Pathogenic role of monoamines in epilepsy
The pathogenic role of 5HT in epilepsy has been suggested in
functional neuroimaging studies using positron emission tomography
(PET) in PWE and in experimental animal models of epilepsy.
3.1.1. Neuroimaging studies
Five studies with PET using various 5HT1A receptor antagonists in
patients with temporal lobe epilepsy demonstrated a decrease of
5HT1A binding in several neuroanatomical structures including the epi-
leptogenic hippocampus, amygdala, and anterior cingulate and lateral
temporal neocortex (ipsilateral to the seizure focus), as well as in the
contralateral hippocampus and in the raphe nuclei [16–20]. Further-
more, reduction in 5HT1A receptor binding has also been found in
generalized epilepsy in the dorsolateral prefrontal cortex, raphe nuclei,and hippocampus of 11 patients with juvenile myoclonic epilepsy
compared to 11 controls [21].
3.2. Experimental data
A potential pathogenic role of 5HT in epilepsy has been suggested in
several animal models of focal and generalized epilepsy. For example,
an abnormal serotonergic axon arborization, associated with deﬁcient
postsynaptic 5HT1A receptor density, has been demonstrated in the
hippocampus of genetically epilepsy-prone rats (GEPRs) [22], an animal
model of generalized epilepsy in which generalized tonic–clonic sei-
zures are induced with audiogenic stimuli. Furthermore, elevation of
5HT levels with the SSRIs ﬂuoxetine, citalopram, and sertraline resulted
in a dose-dependent seizure frequency reduction, which correlated
with the extracellular serotonergic thalamic concentration [23], while
the 5-HT precursor 5-hydroxytriptophan (5-HTP) has been shown to
have anticonvulsant effects when combinedwith amonoamine oxidase
inhibitor (MAOI) [24].
The pathogenic role of 5HT in animal models of focal epilepsy has
also been suggested in a model of status epilepticus in male Wistar
rats, in which Mazarati et al. demonstrated a decrease of hippocampal
5-HT concentration and turnover as well as a lower 5-HT release from
the hippocampus in response to raphe nuclei stimulation [25].
Prendiville et al. demonstrated that ﬂuoxetine prevented seizures
when preadministered in the bicuculline (a GABA antagonist) model
of focal epilepsy in rats [26], while 5HT agonists have been found to
block seizures in other models of focal epilepsy [27].
4. Does 5HT mediate the antiepileptic effect of AEDs?
An increase in extracellular 5HT has been found in theGEPR after the
administration of several ﬁrst and second generation AEDs, including
phenytoin, carbamazepine, valproic acid, lamotrigine, oxcarbazepine,
and zonisamide [24,28–37]. For example, after establishing an anticon-
vulsant effect of carbamazepine in the GEPR, Yan et al. showed that the
addition of 5HT-depleting drugs results in a blockage of this anticonvul-
sant protection [24]. Likewise, Clinckers et al. investigated the impact of
oxcarbazepine (OXC) infusion on the extracellular hippocampal
concentration of 5HT and DA in the focal pilocarpine model for limbic
seizures [31]. When oxcarbazepine was administered together with
verapamil or probenecid (to ensure its passage through the blood–
brain barrier), complete seizure remission was obtained, associated
with an increase in 5HT and DA extracellular concentrations [32].
Furthermore, SSRIs such as ﬂuoxetine enhance the anticonvulsant
effects of phenytoin, carbamazepine, phenobarbital, and valproate in
the maximal electroshock seizure model in mice [30].
The antiepileptic effect of 5HT1A receptors has been associated
with a membrane hyperpolarizing response associated with increased
potassium conductance in hippocampal-kindled seizures in cats and in
intrahippocampal KA-induced seizures in freely moving rats [38,39]. A
recent study has also suggested that the SSRI sertraline could markedly
reduce the increase of proinﬂammatory cytokine expression induced by
seizures and convulsant agents and by the inoculation of lipopolysaccha-
ride in the hippocampus including IL-1β and TNF-αmRNA expression
[40].
The pharmacologic effect of SSRIs inﬂuences other neurotransmitter
systems involved in epileptogenesis and seizure propagation such as
cholinergic neurons in the septum and glutamatergic neurons in the
hippocampus and forebrain regions, where 5HT agonists stimulate ace-
tylcholine and inhibit glutamate release, respectively [41]. Furthermore,
stimulation of 5HT1A receptors in thalamic relay neurons results in an
increase in GABA release and, consequently, a decrease in excitatory ac-
tivity necessary for spike–wave discharges in absence seizure models
[41]. A review by Hamid and Kanner provides a more in-depth discus-
sion of experimental data suggesting an antiepileptic effect of SSRIs [2].
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To date, only open trials of SSRIs and SNRIs in PWE have been
published [42–45]. All were descriptive and suggested that these
drugs had no negative impact on seizure frequency. Two trials sug-
gested a reduction in seizure frequency, but these studies were not
powered to show antiepileptic efﬁcacy and were not controlled. Thus,
an antiepileptic effect of these drugs is yet to be established in PWE.
4.2. Special considerations on the use of antidepressants in PWE
Depressive and anxiety symptomsmay be the expression of an under-
lying interictal disorder, they may represent postictal symptoms, or they
mayhave resulted froman iatrogenic effect of introduction and/or discon-
tinuation of AEDs. Therefore, before starting any pharmacologic
treatment with a psychotropic drug, the following causes of psychiatric
symptoms must be excluded: (1) administration of AEDs with negative
psychotropic properties (e.g., barbiturates, benzodiazepines, topiramate,
levetiracetam, zonisamide, vigabatrin, tiagabine, and perampanel);
(2) discontinuation of AEDs with anxiolytic (e.g., pregabalin and
gabapentin) and/ormood-stabilizing properties (e.g., valproic acid, carba-
mazepine, oxcarbazepine, and lamotrigine) that were keeping an under-
lying anxiety/depressive disorder in remission; and (3) the target
symptoms are preictal, ictal, or postictal symptoms, as these symptoms
do not respond to pharmacotherapy with antidepressants [46–48].
The aim of any type of pharmacologic treatment must be geared
towards complete symptom remission, as persistence of symptoms,
even in the presence of improvement, is associated with a signiﬁcant
risk of recurrence of a major depressive episode (MDE). Furthermore,
antidepressant drugs should not be started in patients with a bipolar
disorder, unless they are taking amood-stabilizing agent, as antidepres-
sants can facilitate the development of manic and hypomanic episodes
or of a rapid cycling bipolar disorder (i.e., four or more depressive,
manic, or hypomanic episodes in a 12-month period) [49].
As stated above, the ﬁrst line of treatment of depressive and anxiety
disorders in patientswith andwithout epilepsy includes the use of SSRIs
or SNRIs. The choice of the speciﬁc SSRIs and/or SNRIs depends on the
following variables: 1) type of depressive episode (SNRIs are preferred
for retarded depressive episodes, e.g., fatigue and slow thinking; other-
wise, patients should be started on an SSRI); 2) therapeutic proﬁle in de-
pressive and anxiety disorders, given their high comorbidity in PWE;
3) potential pharmacokinetic and pharmacodynamic interactions with
concurrent AEDs; and 4) potential adverse event proﬁle of the speciﬁc
SSRI drug that couldworsen underlyingmedical complications associat-
ed with the seizure disorder or other concurrent medical conditions
(i.e., obesity and sexual disturbances). Failure to reach remission of
symptoms following a trial with an SSRI at optimal doses should be
followed by a switch to an SNRI and vice versa.
Patients should be started at a lowdose andwith stepwise increments
until achieving a symptom-free state, developing adverse events, or
reaching the maximal dose, whichever occurs ﬁrst. Table 1 summarizes
the starting and maximal doses of SSRIs and SNRIs, their efﬁcacy inTable 1
Efﬁcacy and doses of SSRIs and SNRIs in primary depression and anxiety disorders.
Antidepressant drug Depression Panic disorder Generalized anxiety Start
Paroxetinea + + + 10
Sertralinea + + + 25
Fluoxetinea + + − 10
Citaloprama + + + 10
Escitaloprama + + + 5
Fluvoxaminea + + + 50
Venlafaxineb + + + 37.5
Duloxetineb + + + 20
+: used for the treatment of this condition.+: has FDA indication for this condition.
a SSRI.
b SNRI.mood and anxiety disorders, and whether they are subject to pharmaco-
kinetic interactions with AEDs.
Furthermore, SSRIs and SNRIs can be associated with relatively fre-
quent adverse events, which require close supervision, and patients
should be advised to alert the clinician upon their occurrence. These in-
clude the following: gastrointestinal symptoms (nausea and diarrhea
with prevalence rates of 35% and 19%, respectively), headaches in 15%,
insomnia in 25%, dry mouth in 13%, and sexual disturbances in 10 to
20% [50]. In addition, osteoporosis and osteopenia have been associated
with these drugs, but the actual prevalence is yet to be established. In
addition, SNRIs can be associated with excessive sweating, hyperten-
sion, and a syndrome of inappropriate antidiuretic hormone secretion
leading to hyponatremia, a potential adverse event identiﬁed in patients
taking venlafaxine (but not duloxetine) [51]. Duloxetine should be used
with great care in patients with a history of liver disease and should be
avoided in those with glaucoma.4.3. Pharmacokinetic properties of antidepressants and interaction with
AEDs
The achievement of the optimal serum concentration of SSRIs and
SNRIs may be prevented when used together with ﬁrst generation
AEDs such as phenytoin, carbamazepine, phenobarbital, and primidone
and the third generation AED ruﬁnamide, which are inducers of the cy-
tochrome p450 (CYP) enzyme system. Oxcarbazepine and topiramate
are much less potent inducers of CYP 3A4. Indeed, the majority of anti-
depressant drugs are substrates for one ormore of the CYP isoenzymes,
and comedication with any of these AEDs would be expected to in-
crease their systemic clearance, speciﬁcally, that of sertraline, paroxe-
tine, citalopram, and escitalopram [52]. Accordingly, their dose must
be increased by 30% in order to ensure an optimal therapeutic antide-
pressant response [52,53]. In contrast to the enzyme-inducing drugs,
the AED sodium valproate can inhibit certain CYP (2C9) and UDP-
glucuronosyltransferase enzymes, but no interaction with SSRIs or
SNRIs has been reported.
By the same token, antidepressants of the SSRI family can inhibit
several CYP isoenzymes [53–55,46–48] with the exception of
citalopram and escitalopram, while sertraline has mild inhibitory ef-
fects. Fluoxetine has been shown to inhibit CYP 3A4, CYP 2C9, CYP
2C19, CYP 2D6, and CYP 1A2. Its metabolite, norﬂuoxetine, has also
been shown to inhibit CYP 2D6, while ﬂuvoxamine is an inhibitor of
CYP 1A2, CYP 3A4, CYP 2C9, and CYP 2C19. Inhibition of CYP 3A4, CYP
2C9, and CYP 2C19 is of the most relevance when considering potential
effects on the currently available AEDs, leading to increased phenytoin
and carbamazepine serum concentrations [52,53,54]. Although deﬁni-
tive studies are lacking, it has also been suggested that venlafaxine
and duloxetine are unlikely to cause signiﬁcant interactions with
currently available AEDs [52,53].
Less clinical data are available regarding pharmacokinetic interac-
tions between antidepressants and the newer generation AEDs. Given
that the newer AEDs are in general less reliant upon the CYP isoenzymeing dose Maximal dose Inhibits some AEDs Clearance increased by EIAED
60 Yes Yes
200 Mild Yes
80 Yes ?
60 No Yes
30 No No
300 Yes No
300 No No
120 No No
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nities for pharmacokinetic interactions.
4.4. Pharmacodynamic interactions between AEDs and antidepressants
One of the concerns that clinicians have to always keep in mind is
the potential worsening of adverse events resulting from the combina-
tion of antidepressant drugs and AEDs that have common adverse
events. Yet, the observations of this section are theoretical with limited
data. From a theoretical standpoint, the following potential synergistic
adverse events have to be looked for carefully:
(1) Potentiation of weight gain that can be caused by AEDs such as
gabapentin, valproic acid, carbamazepine, pregabalin, and the
SSRIs and SNRIs.
(2) Potentiation of sexual adverse events: Sexual adverse events,
such as decreased libido, anorgasmia, and sexual impotence
can be relatively common with AEDs such as the barbiturates
(phenobarbital and primidone) but can also be seen with other
enzyme-inducing AEDs, related to the synthesis of sex-hor-
mone-binding globulin, which binds the free fraction of sex hor-
mones and hence limits their access to the CNS. As mentioned
above, SSRIs and SNRIs are known to cause sexual adverse
events. Whether the combination of this types of AEDs and anti-
depressants has a “synergistic adverse effect” on sexual functions
has yet to be established. The direct impact of the seizure disor-
der on sexual functions is an additional confounding variable
which could, in fact, be the variable responsible for the decreased
sexual drive independently of the exposure to the AEDs and/or
antidepressant drugs.
(3) Potentiation of osteopenia and osteoporosis between enzyme-
inducing AEDs and SSRIs: Several population-based studies have
suggested that exposure to SSRIs is associated with decreased
bonemineral density (BMD) and bone fractures (level IIb). For ex-
ample, one study found higher rates of bone loss at the hip for SSRI
users, even after controlling for possible confounders like depres-
sion [55]. In a Canadian population study, the adjusted odds ratio
for hip fracture was 2.4 (95% CI, 2.0–2.7) for exposure to SSRIs
compared tononusers [56]. A thirdpopulation-based study carried
out in theNetherlands found the risk of nonvertebral fracture to be
2.35 (95% CI, 1.32–4.18) for current users of SSRIs compared with
nonusers of antidepressants, after adjustment for age, sex, lower-
limb disability, and depression [57]. The pathogenic mechanisms
by which SSRIs may cause osteopenia have been attributed in
preclinical studies to the serotonin transporter (which has been
demonstrated in human osteoclasts, osteoblasts, and osteocytes).
Investigators have found that bone mineral accrual was impaired
in growing mice treated with an SSRI [58]. Clearly, these data
raise the question of whether the use of SSRIs increases the risk
of osteopenia and osteoporosis, which has been recognized for a
long time with enzyme-inducing AEDs.
(4) Serum sodium must be monitored when SNRIs are used together
with carbamazepine, oxcarbazepine, and eslicarbazepine.
(5) Excessive sweating may also be associated with lamotrigine, and
sexual dysfunction can worsen a pre-existent disturbance associ-
ated with the seizure disorder or an iatrogenic effect caused by
barbiturates.
5. Concluding remarks
Antidepressant drugs of the SSRI and SNRI families are safe for PWE
and should be used at therapeutic doses for themanagement of depres-
sive and anxiety disorders. Antidepressants can cause seizures at toxic
doses, and only four drugs have revealed proconvulsant effects at ther-
apeutic doses: clomipramine, bupropion, amoxapine, and maprotiline.
Clearly, these drugs should be used with great caution in PWE.Conﬂict of interest
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